Newbury Pharmaceuticals Q2: A bump in the road - Redeye

Redeye provides a research update following the Q2 report published by Newbury yesterday. As the company follows up the impressive Q1 figures with some rather modest sales figures, we make some downward adjustments to our estimates for future sales growth. Having also adjusted for the dilution effect from the recent directed share issue, we revise our base case valuation to SEK8 (9).

Länk till analysen i sin helhet: https://www.redeye.se/research/995181/newbury-pharmaceuticals-q2-a-bump-in-the-road?utm_source=finwire&utm_medium=RSS